In-situ immune markers predict nivolumab (N) plus /-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial

被引：2
|
作者：
Meylan, M.
Sun, C-M.
Elaidi, R-T.
Moreira, M.
Bougouin, A.
Verkarre, V.
Bennamoun, M.
Chevreau, C. M.
Borchiellini, D.
Barthelemy, P.
Pannier, D.
Maillet, D.
Goupil, M. Gross
Tournigand, C.
Braychenko, E.
Phan, L.
Oudard, S.
Fridman, W-H.
Sautes-Fridman, C.
Vano, Y-A.
机构：
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1451MO
引用
收藏
页码：S1207 / S1207
页数：1
相关论文
共 50 条
  • [21] Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study
    Izumi, Keita
    Inoue, Masaharu
    Washino, Satoshi
    Shirotake, Suguru
    Kagawa, Makoto
    Takeshita, Hideki
    Miura, Yuji
    Hyodo, Yoji
    Oyama, Masafumi
    Kawakami, Satoru
    Miyagawa, Tomoaki
    Saito, Kazutaka
    Kageyama, Yukio
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (09) : 714 - 721
  • [22] Reasonability of Frequent Laboratory Analyses during Therapy with Nivolumab and Nivolumab plus Ipilimumab in Patients with Advanced or Metastatic Renal Cell Carcinoma during the Phase 2 Clinical Trial TITAN-RCC
    Franke, Klara
    Foller, Susan
    Moreno, Michele Estephania Rosero
    Ali, Nalyan
    Leistritz, Lutz
    Leucht, Katharina
    Grimm, Marc-Oliver
    CANCERS, 2024, 16 (12)
  • [23] Ipilimumab/nivolumab (I/N) compared to axitinib/pembrolizumab (A/P) in metastatic renal cell carcinoma (mRCC): Insights from a Canadian population.
    Ohm, Hyejee
    Ghosh, Sunita
    Gupta, Mehul
    Wood, Lori
    Castonguay, Vincent
    Graham, Jeffrey
    Kollmannsberger, Christian K.
    Bosse, Dominick
    Soulieres, Denis
    Heng, Daniel Yick Chin
    Fallah-Rad, Nazanin
    Finelli, Antonio
    Tanguay, Simon
    Lalani, Aly-Khan A.
    Bhindi, Bimal
    Bjarnason, Georg A.
    Breau, Rodney H.
    Pouliot, Frederic
    Basappa, Naveen S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 393 - 393
  • [24] Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.
    Emamekhoo, Hamid
    Olsen, Mark R.
    Carthon, Bradley Curtis
    Drakaki, Alexandra
    Percent, Ivor John
    Molina, Ana M.
    Cho, Daniel C.
    Bendell, Johanna C.
    Gordan, Lucio N.
    Kalebasty, Arash Rezazadeh
    George, Daniel J.
    Hutson, Thomas E.
    Arrowsmith, Edward
    Zhang, Joshua
    Zoco, Jesus
    Johansen, Jennifer L.
    Leung, David
    Tykodi, Scott S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial
    Vano, Yann-Alexandre
    Elaidi, Reza
    Bennamoun, Mostefa
    Chevreau, Christine
    Borchiellini, Delphine
    Pannier, Diane
    Maillet, Denis
    Gross-Goupil, Marine
    Tournigand, Christophe
    Laguerre, Brigitte
    Barthelemy, Philippe
    Coquan, Elodie
    Gravis, Gwenaelle
    Houede, Nadine
    Cancel, Mathilde
    Huillard, Olivier
    Beuzeboc, Philippe
    Fournier, Laure
    Mejean, Arnaud
    Cathelineau, Xavier
    Doumerc, Nicolas
    Paparel, Philippe
    Bernhard, Jean-Christophe
    de la Taille, Alexandre
    Bensalah, Karim
    Tricard, Thibault
    Waeckel, Thibaut
    Pignot, Geraldine
    Braychenko, Elena
    Caruso, Stefano
    Sun, Cheng-Ming
    Verkarre, Virginie
    Lacroix, Guillaume
    Moreira, Marco
    Meylan, Maxime
    Bougouin, Antoine
    Phan, Letuan
    Thibault-Carpentier, Christelle
    Zucman-Rossi, Jessica
    Fridman, Wolf Herman
    Sautes-Fridman, Catherine
    Oudard, Stephane
    LANCET ONCOLOGY, 2022, 23 (05): : 612 - 624
  • [26] Real-world safety and efficacy data of patients with synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N plus I) and the primary tumour (PT) in place.
    Meerveld-Eggink, Aafke
    Graafland, Niels
    Wilgenhof, Sofie
    Van Thienen, Johannes V.
    Grant, Michael
    Szabados, Bernadett
    Abu-Ghanem, Yasmin
    Boleti, Ekaterini
    Blank, Christian U.
    Haanen, John B. A. G.
    Powles, Thomas
    Bex, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Real-world utilization and safety of ipilimumab plus nivolumab (I plus N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis)
    Thana, Myuran
    Basappa, Naveen S.
    Ghosh, Sunita
    Kollmannsberger, Christian K.
    Heng, Daniel Yick Chin
    Graham, Jeffrey
    Soulieres, Denis
    Hansen, Aaron Richard
    Lalani, Aly-Khan A.
    Castonguay, Vincent
    Reaume, M. Neil
    Bjarnason, Georg A.
    Breau, Rodney H.
    Pouliot, Frederic
    Kapoor, Anil
    Wood, Lori
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [28] Prognostic value of the lung immune prognostic index in patients with untreated advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (N plus I) or sunitinib (SUN) in the CheckMate 214 trial.
    Carril-Ajuria, Lucia
    Motzer, Robert J.
    Tannir, Nizar M.
    McDermott, David F.
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Donskov, Frede
    Rini, Brian I.
    Jiang, Ruiyun
    Lee, Chung-Wei
    Desilva, Heshani
    Albiges, Laurence
    Roussy, Gustave
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] Editorial Comment on Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study
    Yuasa, Takeshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2023,
  • [30] Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and low Karnofsky performance status: Results from the CheckMate 920 trial.
    Hutson, Thomas E.
    Carthon, Bradley Curtis
    Yorio, Jeffrey
    Babu, Sunil
    McKean, Heidi Ann
    Percent, Ivor John
    Tykodi, Scott S.
    Harrison, Michael Roger
    Zhang, Joshua
    Zoco, Jesus
    Johansen, Jennifer L.
    George, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345